N4 Pharma (GB:N4P) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
N4 Pharma PLC, a specialist pharmaceutical company, has announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director. Dr. Palfreyman brings over four decades of drug discovery and development experience, having held significant roles in major pharmaceutical companies and biotech startups, and is expected to contribute greatly to N4 Pharma’s efforts to commercialize their novel delivery system, Nuvec®.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.